YUTIQ® (fluocinolone acetonide intravitreal implant) 0.18 mg is indicated for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye.

Patient 3

1.5-Month Follow-up After YUTIQ Treatment

Presentation at 1.5-Month Follow-up

IOP19 mmHg
Vitreous cellClear
Fundus exam findingsDry macula

Patient’s vision has improved and is stable.

Continue to monitor for IOP elevations and inflammation recurrence.

Imaging at 1.5-Month Follow-up